MarketScreener Homepage > Equities > NASDAQ OMX COPENHAGEN > Novo Nordisk A/S NOVO B DK0060534915

Report

Real-time Estimate CHI-X - 10/26 10:01:40 am
442.95	DKK		-0.52%

08:48a

NOVO NORDISK A/S : – Share repurchase programme

10/16

NOVO NORDISK : Buy rating from Goldman Sachs

10/14

NOVO NORDISK : Buy rating from JP Morgan

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq Omx Copenhagen

10/20/2020	10/21/2020	10/22/2020	10/23/2020	10/26/2020	Date
451(c)	446.35(c)	444.1(c)	445.25(c)	443.15	Last
1 793 081	2 380 102	2 474 490	1 558 012	730 637	Volume
-0.03%	-1.03%	-0.50%	+0.26%	-0.47%	Change

More quotes

Financials

Sales 2020	128 B 20 316 M 20 316 M
Net income 2020	42 262 M 6 716 M 6 716 M
Net cash position 2020	10 720 M 1 703 M 1 703 M
P/E ratio 2020	24,7x
Yield 2020	2,03%

Sales 2021	136 B 21 589 M 21 589 M
Net income 2021	45 585 M 7 244 M 7 244 M
Net cash position 2021	14 977 M 2 380 M 2 380 M
P/E ratio 2021	22,3x
Yield 2021	2,19%

Capitalization	1 035 B 165 B 164 B
EV / Sales 2020	8,01x
EV / Sales 2021	7,51x
Nbr of Employees	43 526
Free-Float	75,1%

More Financials

Company

Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of...

Sector

Pharmaceuticals

Calendar

10/30

Earnings Release

More about the company

Notations Surperformance© of Novo Nordisk A/S

Trading Rating :

Investor Rating :

More Ratings

All news about NOVO NORDISK A/S

08:48a	NOVO NORDISK A/S : – Share repurchase programme	AQ
10/16	NOVO NORDISK : Buy rating from Goldman Sachs	MD
10/14	NOVO NORDISK : Buy rating from JP Morgan	MD
10/12	NOVO NORDISK : Credit Suisse gives a Buy rating	MD
10/12	NOVO NORDISK A/S : Bavarian Nordic Announces Appointment of Anu Helena Kerns as ..	AQ
10/12	NOVO NORDISK A/S : Conference call regarding updated 2020 outlook 9 October 2020	PU
10/12	NOVO NORDISK A/S : Alexander Mann Solutions partners with Novo Nordisk to suppor..	AQ
10/12	NOVO NORDISK A/S : – Share repurchase programme	AQ
10/09	EUROPE : European stocks rack up second week of gains, Pandora leaps	RE
10/09	NOVO NORDISK : Credit Suisse gives a Buy rating	MD
10/09	GLOBAL MARKETS LIVE : Acquisitions, acquisitions, acquisitions
10/09	Sobi shares fall 17% as Avatrombopag study fails to meet primary endpoint	RE
10/09	NOVO NORDISK : UBS sticks Neutral	MD
10/09	NOVO NORDISK : DZ Bank reiterates its Sell rating	MD
10/09	NOVO NORDISK : Sell rating from Jefferies	MD

More news

News in other languages on NOVO NORDISK A/S

10/16	NOVO NORDISK : Goldman Sachs toujours positif
10/16	Goldman belässt Novo Nordisk auf 'Conviction Buy List'
10/14	NOVO NORDISK : JP Morgan maintient sa recommandation à l'achat
10/14	JPMorgan belässt Novo Nordisk auf 'Overweight' - Ziel 480 Kronen
10/12	NOVO NORDISK : Credit Suisse toujours positif

More news

Analyst Recommendations on NOVO NORDISK A/S

10/16	NOVO NORDISK : Buy rating from Goldman Sachs	MD
10/14	NOVO NORDISK : Buy rating from JP Morgan	MD
10/12	NOVO NORDISK : Credit Suisse gives a Buy rating	MD

More recommendations

Provided by Scoopnest.com

Analysis

New $1 billion fund aims to steer antibiotic companies in tough market

More Must read

Stock Pick

NOVO NORDISK AS
Global leader in diabetes treatments

More Recommendations

Chart NOVO NORDISK A/S

Duration : Period :

Novo Nordisk A/S Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends NOVO NORDISK A/S

	Short Term	Mid-Term	Long Term
Trends	Neutral	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	25
Average target price	447,63 DKK
Last Close Price	445,25 DKK
Spread / Highest target	22,4%
Spread / Average Target	0,53%
Spread / Lowest Target	-31,5%

Consensus

EPS Revisions

More Estimates Revisions

Managers

Name	Title
Lars Fruergaard Jørgensen	President & Chief Executive Officer
Helge Lund	Chairman
Maziar Mike Doustdar	Executive Vice President-International Operations
Karsten Munk Knudsen	Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen	Chief Science Officer & Executive Vice President

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

NOVO NORDISK A/S	15.16%	164 690



JOHNSON & JOHNSON	-0.43%	382 350
ROCHE HOLDING AG	-5.29%	280 884
PFIZER INC.	-2.55%	212 162
MERCK & CO., INC.	-12.23%	201 909
NOVARTIS AG	-16.78%	185 999

More Results